Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
TelyRx HoldingsTSX:TELY +13.04%12 Debt-to-Equity is 0.91 as of Mar. 2026. GuruFocus rates TSX:TELY with a GF Score™ of 12/100. The stock has 1 warning sign investors should review. Among 557 Healthcare Providers & Services companies, TelyRx Holdings ranks worse than 71.27% on this metric.
A high debt to equity ratio generally means that a company has been aggressive in financing its growth with debt. This can result in volatile earnings as a result of the additional interest expense.
The historical rank and industry rank for TelyRx Holdings's Debt-to-Equity or its related term are showing as below:
TSX:TELY'
s Debt-to-Equity Range Over the Past 10 Years
Min: -4.08 Med: -1.85 Max: 0.91
Current: 0.91
During the past 3 years, the highest Debt-to-Equity Ratio of TelyRx Holdings was 0.91. The lowest was -4.08. And the median was -1.85.
TSX:TELY's Debt-to-Equity is ranked worse than 71.27% of 557
companies
in the Healthcare Providers & Services industry
Industry Median: 0.41
vs TSX:TELY: 0.91
Because a company can increase its ROE % by having more financial leverage, it is important to watch the leverage ratio when investing in high ROE % companies.
TelyRx Holdings Debt-to-Equity Related Terms
TelyRx Holdings Debt-to-Equity Historical Data
* Premium members only.
The historical data trend for TelyRx Holdings's Debt-to-Equity can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Pharmaceutical Retailers subindustry, TelyRx Holdings's Debt-to-Equity, along with its competitors' market caps and Debt-to-Equity data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
TelyRx Holdings Debt-to-Equity vs Healthcare Providers & Services Industry
For the Healthcare Providers & Services industry and Healthcare sector, TelyRx Holdings's Debt-to-Equity distribution charts can be found below:
* The bar in red indicates where TelyRx Holdings's Debt-to-Equity falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
TelyRx Holdings (TSX:TELY) has a Debt-to-Equity of 0.91 as of Mar. 2026. Debt-to-Equity ratio represents the ratio of total debt to total company equity. View historical data on TelyRx Holdings and its competitors. According to the industry distribution chart, TelyRx Holdings ranks #397 out of 557 companies in the Healthcare Providers & Services industry, placing it in the top 71.3%.
Is TelyRx Holdings' Debt-to-Equity too high?
TelyRx Holdings' current Debt-to-Equity is 0.91. The Healthcare Providers & Services industry median Debt-to-Equity is 0.41. TelyRx Holdings' value of 0.91 is 122% above this industry median. Based on the distribution chart, TelyRx Holdings ranks #397 out of 557 companies in the Healthcare Providers & Services industry, which is below the industry midpoint. Overall, TelyRx Holdings has a GF Score™ of 12/100, reflecting its overall financial health beyond just this single metric.
How does TelyRx Holdings' Debt-to-Equity compare to competitors?
According to the Healthcare Providers & Services industry distribution chart, TelyRx Holdings ranks #397 out of 557 companies for Debt-to-Equity. This places TelyRx Holdings in the lower half of its industry. The industry median Debt-to-Equity is 0.41. TelyRx Holdings' value of 0.91 is 122% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Debt-to-Equity for a Healthcare Providers & Services company?
The median Debt-to-Equity among Healthcare Providers & Services companies is 0.41, based on 557 companies in the industry. Companies in the top quartile (top 25%) have a Debt-to-Equity significantly above this median, while those in the bottom quartile fall well below. However, Debt-to-Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. TelyRx Holdings's current Debt-to-Equity of 0.91 is 122% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Debt-to-Equity mean?
A high Debt-to-Equity can signal that a stock is expensive relative to its fundamentals. Debt-to-Equity ratio represents the ratio of total debt to total company equity. View historical data on TelyRx Holdings and its competitors. For the Healthcare Providers & Services industry, the median Debt-to-Equity is 0.41 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. TelyRx Holdings's current Debt-to-Equity is 0.91. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is TelyRx Holdings stock overvalued right now?
TelyRx Holdings (TSX:TELY) has a current Debt-to-Equity of 0.91. The current Debt-to-Equity is 0.91 and 122% above the Healthcare Providers & Services industry median of 0.41. TelyRx Holdings' overall GF Score™ is 12/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Debt-to-Equity calculated?
Debt-to-Equity is calculated from a company's financial statements. For TelyRx Holdings (TSX:TELY), the current Debt-to-Equity is 0.91 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
TelyRx Holdings Inc is a vertically integrated technology enabled healthcare and pharmacy services provider, operating a digital pharmacy platform that connects patients with independent, state-licensed providers. The TelyRx platform provides the Providers with access to a clinically focused electronic medical records system and the ability for them to electronically prescribe. TelyRx enables patient access to a risk-curated formulary of over 450 noncontrolled, and non-compounded prescription medications selected by the Providers to address a broad cross-section of everyday chronic and acute ailments.
12GF Score
Get the complete analysis for TSX:TELY
Debt-to-Equity is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
TSX:TELY has been successfully added to your 
